Second-trimester maternal serum markers in the prediction of preeclampsia

2017 ◽  
Vol 45 (7) ◽  
Author(s):  
Qiong Luo ◽  
Xiujun Han
Keyword(s):  
Detection Rate ◽  
Late Onset ◽  
Serum Levels ◽  
Serum Markers ◽  
Maternal Serum ◽  
Second Trimester ◽  
Third Trimester ◽  
Roc Curve Analysis ◽  
The Third ◽  
Significant Difference

AbstractAim:To determine whether late second-trimester maternal serum biomarkers are useful for the prediction of preeclampsia during the third trimester, a case-control study including 33 preeclamptic and 71 healthy pregnancies was conducted. Maternal serum concentrations of placental protein 13 (PP13), pregnancy-associated plasma protein (PAPP-A), pentraxin3 (PTX3), soluble FMS-like tyrosine kinase-1 (sFlt-1), myostatin and follistatin-like-3 (FSLT-3) were measured at 24–28 weeks’ gestation. All the concentrations of these markers were compared between the preeclamptic and control groups. Receiver operating characteristic (ROC) curve analysis was applied to assess sensitivity and specificity of serum markers with significant difference.Results:The levels of PP13 and sFlt-1 were significantly increased and FSLT3 was significantly decreased in patients with preeclampsia. However, the concentration of PAPPA, PTX3 and myostatin did not differ significantly. In screening for preeclampsia during the third trimester by PP13, sFlt-1 and FSLT3, the detection rate was 61.3%, 48.1% and 39.1%, respectively, at 80% specificity, and the detection rate increased to 69.8% by combination of these three markers.Conclusion:Maternal serum levels of PP13, sFlt-1 and FSLT3 play an important role in predicting late-onset preeclampsia, and the combination of these three markers significantly increases the detection rate for prediction.

scholarly journals P13.11: Maternal serum levels of PlGF and sFlt‐1 in a low‐risk population of pregnant women in the third trimester in predicting pre‐eclampsia

2019 ◽  
Vol 54 (S1) ◽  
pp. 198-198
Author(s):  
L. Roubalova ◽  
K. Langova ◽  
V. Kroutilova ◽  
V. Durdova ◽  
T. Kratochvilova ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Serum Levels ◽  
Maternal Serum ◽  
Low Risk ◽  
Third Trimester ◽  
Risk Population ◽  
The Third

scholarly journals Therapeutic levetiracetam monitoring during pregnancy: “mind the gap”

2019 ◽  
Vol 10 ◽  
pp. 204062231985165 ◽  
Author(s):  
Maya Berlin ◽  
Dana Barchel ◽  
Revital Gandelman-Marton ◽  
Nurit Brandriss ◽  
Ilan Blatt ◽  
...  
Keyword(s):  
Reference Range ◽  
Serum Levels ◽  
First Trimester ◽  
Second Trimester ◽  
Serum Concentrations ◽  
Third Trimester ◽  
The Third ◽  
Antiepileptic Medication ◽  
Apparent Clearance ◽  
Neurological Conditions

Background: Epilepsy is one of the most common chronic neurological conditions and its treatment during pregnancy is challenging. Levetiracetam (LEV) is an antiepileptic medication frequently used during pregnancy. Only a few small studies have been published on LEV monitoring during pregnancy, demonstrating decreased serum LEV levels during the first and second trimester; however, the most significant decrease was observed during the third trimester of pregnancy. In this study we aimed to evaluate LEV pharmacokinetics during different stages of pregnancy. Methods: We followed up and monitored serum levels of pregnant women treated with LEV for epilepsy. Results: Fifty-nine women with 66 pregnancies during the study period were included. The lowest raw LEV serum concentrations were observed during the first trimester. Compared with the pre-pregnancy period, raw serum concentration was lower by 5.76 mg/L [95% confidence interval (CI) (2.78, 8.75), p = 0.039] during the first trimester. Comparing the decrease in the first trimester with either the second or the third, no significant changes were observed ( p = 0.945, p = 0.866). Compared with pre-pregnancy measurements, apparent clearance was increased by 71.08 L/day [95%CI (16.34, 125.83), p = 0.011] during the first trimester. About 30% of LEV serum levels during pregnancy were below the laboratory quoted reference range. Conclusions: Raw LEV serum levels tend to decrease during pregnancy, mainly during the first trimester contrary to previous reports. Monitoring of LEV serum levels is essential upon planning pregnancy and thereafter if pre-pregnancy LEV levels are to be maintained. However, more studies are needed to assess the correlation with clinical outcome.

Maternal Serum Levels of Alpha-Fetoprotein and Fetal Fibronectin as Markers of Labor in the Third Trimester

1995 ◽  
Vol 12 (03) ◽  
pp. 161-163 ◽  
Author(s):  
Meena Khandelwal ◽  
Lauren Lynch ◽  
Charles Lockwood ◽  
Eugene Ainbender
Keyword(s):  
Serum Levels ◽  
Maternal Serum ◽  
Alpha Fetoprotein ◽  
Third Trimester ◽  
Fetal Fibronectin ◽  
The Third

Second-Trimester Levels of Maternal Serum Human Chorionic Gonadotropin and Inhibin A as Predictors of Preeclampsia in the Third Trimester of Pregnancy

2000 ◽  
Vol 7 (3) ◽  
pp. 170-174 ◽  
Author(s):  
Geralyn M. Lambert-Messerlian ◽  
Helayne M. Silver ◽  
Felice Petraglia ◽  
Stefano Luisi ◽  
Ilaria Pezzani ◽  
...  
Keyword(s):  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Maternal Serum ◽  
Second Trimester ◽  
Third Trimester ◽  
Inhibin A ◽  
The Third

scholarly journals Outcomes  of intra-amniotic injection of ethacridine lactate for pregnancy termination in the third trimester or pregnancy termination in women with prior cesarean section

2020 ◽  
Author(s):  
Fangfang Lu ◽  
Wenjun Tang ◽  
Wanchao Wang ◽  
Guiyan Tang ◽  
Xin Huang ◽  
...  
Keyword(s):  
Cesarean Section ◽  
Pregnancy Termination ◽  
Second Trimester ◽  
Cesarean Sections ◽  
Third Trimester ◽  
The Third ◽  
Trimester Pregnancy ◽  
Significant Difference ◽  
Ethacridine Lactate ◽  
History Of

Abstract Background: This study aimed to evaluate the safety and efficacy of the intra-amniotic injection of ethacridine lactate in third trimester pregnancy patients and in patients with a history of cesarean section to induce labor.Methods : This retrospective clinical investigation analyzed 270 patients who underwent second or third trimester pregnancy termination at the affiliated hospital of Guangxi Guilin Medical University between January 1, 2017 and February 29, 2020, including those with and without cesarean section histories. Clinical characteristics and outcomes of all patients were analyzed following treatment with ethacridine lactate.Results: A total of 270 patients were hospitalized for pregnancy terminations, including 234 patients in a second trimester group, 36 patients in a third trimester group, 209 patients in a non-cesarean section group, and 61 patients in a cesarean section group. Among the 270 patients studied, five had twin pregnancies, and eight had two previous cesarean sections. All the included cases had successful vaginal delivery. There was no significant difference in prenatal and postpartum hemoglobin, incidence of massive hemorrhage, the rate of residual placenta and membranes, manual removal of placenta, uterine curettage,and blood transfusion between the second and third trimester groups (P > 0.05), as well as between the non-cesarean and cesarean section groups (P > 0.05). The abortion interval (AI) in the second trimester group was longer than that in the third trimester group (P = 0.014), and the hemorrhage of delivery in the third trimester group was significantly higher than in the second trimester group (P = 0.019). The hemorrhage of delivery in the cesarean section group was higher than that in the non-cesarean section group but displayed no significant difference (P > 0.05). No uterine rupture and placental abruption occurred in any of the patients.Conclusions : Intra-amniotic injection of ethacridine lactate demonstrated good clinical effects and could be used as a suitable method for third trimester pregnancy termination or pregnancy termination in women with prior cesarean sections, and it can also be used to induce labor in the second trimester for twin pregnancies and in patients with a history of two cesarean sections.

scholarly journals The Difference in Average of Maternal Serum Hypoxia-Inducible Factors-1α Levels between Early Onset and Late-Onset Severe Preeclampsia

2021 ◽  
Vol 5 (1) ◽  
pp. 82-89
Author(s):  
David Perdana ◽  
Defrin Defrin ◽  
Firdawati Firdawati
Keyword(s):  
Early Onset ◽  
Sampling Method ◽  
Late Onset ◽  
Serum Levels ◽  
Maternal Serum ◽  
Severe Preeclampsia ◽  
Exclusion Criteria ◽  
Cross Sectional ◽  
Significant Difference ◽  
The Difference

The purpose of this study is to know the difference average of maternal serum levels of HIF-1α between early-onset and late-onset severe preeclampsia. This study used a cross sectional comparative study design that conducted in Februari 2020 - Agustus 2020 in the SMF / Obstetrics and Gynecology department of RSUP dr. M. Djamil Padang, RSUD Achmad Mochtar, RSUD Pariaman, RSUD M Zein Painan. We used consecutive sampling method which consists of 60 pregnant women who fulfill the inclusion and exclusion criteria. They were divided into two groups early-onset severe preeclampsia and late-onset severe preeclampsia. HIF-1α tests were done using ELISA method. The average of maternal serum levels of HIF-1α in late-onset severe preeclampsia is found to be the highest when compared to the early-onset severe preeclampsia, 1,37 ± 1,08 ng/ml vs 0,69 ± 0,11 ng/ml. This difference is significant with the Mann-whitney non parametrical statistical test (p <0.05). There is a significant difference average of maternal serum levels of HIF-1α between early-onset and late-onset severe preeclampsiaKeywords: early onset severe preeclampsia, late onset preeclampsia late onset, maternal serum levels of  HIF-1α

scholarly journals The Difference in Maternal Serum Hypoxia-Inducible Factors-1α Levels between Early Onset and Late-Onset Preeclampsia

2019 ◽  
Vol 7 (13) ◽  
pp. 2133-2137 ◽  
Author(s):  
Roza Sriyanti ◽  
Johanes C. Mose ◽  
Masrul Masrul ◽  
Netti Suharti
Keyword(s):  
Early Onset ◽  
Late Onset ◽  
Serum Levels ◽  
Normal Pregnancy ◽  
Maternal Serum ◽  
Hypoxia Inducible Factors ◽  
Cross Sectional ◽  
Significant Difference ◽  
The Difference ◽  
Early Onset Preeclampsia

BACKGROUND: Preeclampsia can be divided into early (EOPE) and late (LOPE) onset preeclampsia. Preeclampsia is related to the failure of placentation. Accumulation of hypoxia-inducible factors (HIF)-1α is commonly an acute and beneficial respond to hypoxia, while chronically elevated is associated with preeclampsia. AIM: This study aims to evaluate the serum levels of HIF-1α in preeclampsia and normal pregnancy, and to compare the difference between early-onset and late-onset preeclampsia. METHODS: A cross-sectional comparative study was conducted among a total of 69 pregnant women at ≥ 20 weeks of gestation, were recruited at obstetrics and gynaecology department at Dr M. Djamil Padang Hospital, network hospitals, health centres. They were divided into three groups early-onset preeclampsia, late-onset preeclampsia, and normal pregnancy. Preeclampsia was diagnosed using International Guidelines. Data were analysed by SPSS 24 program; data are presented as median and range or as mean ± standard deviation. One-way ANOVA test was used to determine the relationship between HIF-1α levels with the onset of preeclampsia. RESULTS: The results showed that the mean maternal serum HIF-1α levels in early-onset preeclampsia (EOPE), late-onset preeclampsia (LOPE), and normal pregnancy were 1366.96 ± 733.40 pg/ml, 916.87 ± 466.06 pg/ml, and 716.77 ± 541.08 pg/ml. Serum HIF-1α levels were higher in early-onset preeclampsia (EOPE), and late-onset preeclampsia (LOPE) compared to normal pregnancy. Among preeclampsia patients, serum HIF-1α was higher in EOPE than LOPE women. Statistical analysis revealed a significant difference in mean maternal serum HIF-1α between early-onset preeclampsia, late-onset preeclampsia, and normal pregnancy (p < 0.05). CONCLUSION: This study concluded that there is a significantly different level of HIF-1α between in early-onset preeclampsia, late-onset preeclampsia and normal pregnancy. Early-onset preeclampsia is the highest levels of serum HIF-1α.

scholarly journals Does maternal serum progesterone level in early pregnancy predict placental dysfunction in third trimester?

2021 ◽  
Vol 29 (1) ◽  
pp. 39-45
Author(s):  
Gülşen Doğan Durdağ ◽  
Şafak Yılmaz Baran ◽  
Songül Alemdaroğlu ◽  
Hakan Kalaycı ◽  
Seda Yüksel Şimşek ◽  
...  
Keyword(s):  
Early Pregnancy ◽  
Threshold Value ◽  
First Trimester ◽  
Maternal Serum ◽  
Third Trimester ◽  
Serum Progesterone ◽  
The Third ◽  
Placental Dysfunction ◽  
Significant Difference ◽  
Relationship Of

Objective Progesterone, which is necessary for maintenance of pregnancy, is secreted by corpus luteum until 10 weeks of gestation, and is produced from the placenta afterwards. Aim of this study is to investigate the relationship of serum progesterone concentrations measured in 6–8 weeks and 12 weeks of gestation with the parameters that may demonstrate placental dysfunction in the third trimester. Methods Relationship of the progesterone values measured at 6–8 weeks and 12 weeks of gestation with indicators of placental dysfunction, including hypertensive disorders of pregnancy, intrauterine growth restriction, preterm delivery and low birth weight, were evaluated. Furthermore, based on a previous study, two groups with progesterone levels below and above 11 ng/mL in early pregnancy were formed, and the difference between these groups regarding gestational outcomes were investigated. Results Progesterone concentrations at 6–8 and 12 weeks of gestation were not significantly different between the subgroups with and without gestational complications indicating placental dysfunction (p>0.05 for all parameters). As for the two groups, significant difference was not found in terms of third trimester complications due to progesterone cut-off of 11 ng/mL at 6-8 weeks of gestation. Conclusion In this study, we did not find progesterone values measured at early and late first trimester periods to be associated with placental dysfunction in the third trimester. Also, we did not validate a previously suggested threshold value to predict gestational outcome. Therefore, routine first trimester progesterone screening in guiding pregnancy follow-up may not be appropriate.

Sign in / Sign up

Export Citation Format

Share Document